Literature DB >> 15203160

Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.

Takashi Okamura1, Yasuhisa Kurogi, Kinji Hashimoto, Seiji Sato, Hiroshi Nishikawa, Kimio Kiryu, Yoshimitsu Nagao.   

Abstract

Structure-activity relationships (SAR) of fused 1,2,4-triazolo[1,5-c ]pyrimidine were performed. Various substituents were introduced into the heterocyclic ring to improve the potency of adenosine A(3) receptor binding affinity and A(3)-selectivity against other subtypes. Potent and selective A(3) receptor antagonists were identified and were evaluated in a monkey model of intraocular pressure by eye-drop administration. As a result, compound 1c (OT-7999) was found to significantly decrease intraocular pressure in the animal model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203160     DOI: 10.1016/j.bmcl.2004.04.099

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

1.  Novel fluorescent antagonist as a molecular probe in A(3) adenosine receptor binding assays using flow cytometry.

Authors:  Eszter Kozma; T Santhosh Kumar; Stephanie Federico; Khai Phan; Ramachandran Balasubramanian; Zhan-Guo Gao; Silvia Paoletta; Stefano Moro; Giampiero Spalluto; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2012-03-01       Impact factor: 5.858

Review 2.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

Review 3.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

4.  Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

Authors:  Zhan-Guo Gao; Bhalchandra V Joshi; Athena M Klutz; Soo-Kyung Kim; Hyuk Woo Lee; Hea Ok Kim; Lak Shin Jeong; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2005-11-10       Impact factor: 2.823

Review 5.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 6.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

Review 7.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

Review 8.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

9.  The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.

Authors:  Hui Yang; Marcel Y Avila; Kim Peterson-Yantorno; Miguel Coca-Prados; Richard A Stone; Kenneth A Jacobson; Mortimer M Civan
Journal:  Curr Eye Res       Date:  2005-09       Impact factor: 2.424

10.  2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists.

Authors:  Liesbet Cosyn; Krishnan K Palaniappan; Soo-Kyung Kim; Heng T Duong; Zhan-Guo Gao; Kenneth A Jacobson; Serge Van Calenbergh
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.